Head of Investor Relations
Ligand Pharmaceuticals Inc (LGND)Equibles does not estimate personal net worth.
Get an email with a short summary when Ligand Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get LGND alertsMelanie Herman is recorded as Head of Investor Relations at Ligand Pharmaceuticals Inc (LGND). Melanie Herman has spoken on 8 earnings calls across 1 company, most recently for Ligand Pharmaceuticals Inc on October 29, 2026. Ligand Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ligand Pharmaceuticals Inc includes Todd C. Davis (CEO and Board Member), Tavo Espinoza (CFO), Jason Haas (Board Member) and 7 others.
“With me on the call today are CEO Todd Davis, Chief Financial Officer Thabo Espinoza, Vice President of Portfolio Strategy and Investments Lauren Hay, and Paul Haddon, Senior Vice President of Investments and Business Development.”
“With me on the call today are CEO Todd Davis, Chief Financial Officer Tavo Espinoza, and Vice President of Portfolio Strategy and Investments Lauren Hay.”
“With me on the call today are CEO Todd Davis, Chief Financial Officer Tavo Espinosa, Vice President of Portfolio Strategy and Investments Lauren Hay, and Vice President of Investments and Business Development Michael Vigilante.”
“Good morning, everyone, and welcome to LIGAN's fourth quarter and full year 2025 earnings With me on the call today are CEO Todd Davis, Chief Financial Officer Tavo Espinoza, and Vice President of Portfolio Strategy and Investments Lauren Hay.”
“During the call today, we will review the financial results we released earlier today and provide commentary on our partner pipeline and business development activity, followed by a question and answer session.”
Biotechnology · Healthcare
Head of Investor Relations
